Media and briefings
Latest posts
Just the Facts: Prescient Therapeutics secures FDA approval for PTX-100 Phase 2 trials
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF). The company has ...
Read More
Read More
Just the Facts: Prescient Therapeutics secures FDA approval for PTX-100 Phase 2 trials
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF). The company has ...
Read More
Read More
Prescient Therapeutics welcomes US FDA allowance of Investigational New Drug application for PTX-100 Phase 2 clinical trial
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is trading higher after receiving a green light from the US Food and Drug Administration (FDA) to proceed ...
Read More
Read More
Prescient Therapeutics appoints experienced pharmaceuticals executive James McDonnell as CEO
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), which is developing a pipeline of targeted, personalised therapies for cancer, has tapped ...
Read More
Read More
Miles Prince Q&A Update
Reach Markets recently interviewed Professor H. Miles Prince AM – the Principal Investigator of our PTX-100 program – regarding its ...
Read More
Read More
STAY UP TO DATE
Register your details to receive company updates from Prescient Therapeutics
WEBCAST AND MEDIA
Prescient Therapeutics (ASX: PTX) Investor Q&A - 25 March 2024
Pitt Street Research Briefing on Prescient Therapeutics - 14 March 2024
Prescient Therapeutics: PTX-100 targeted cell therapy briefing - 18 December 2023
Pitt Street Research Briefing on Prescient Therapeutics - 22 November 2023
Prescient Therapeutics (ASX: PTX) Investor Q&A - 8 November 2023
Prescient Therapeutics TechKnow Invest Roadshow - 2 August 2023
Prescient Therapeutics: Cell Therapies presentations from ISCT - 8th June 2023
Prescient Therapeutics Meeting on the Med Conference - April 2023
Prescient Therapeutics: PTX-100 targeted cell therapy briefing - 2nd March 2023
Prescient Therapeutics CellPryme-A Briefing - 27 September 2022
Prescient Therapeutics (ASX:PTX) Investor Webcast - 10 June 2022
Prescient Therapeutics (ASX:PTX) Investor Webcast - 3 March 2022
Prescient Therapeutics (ASX:PTX) Investor Webcast - 19 October 2021
Prescient Therapeutics & Peter MacCallum Collaboration Update
Prescient Therapeutics with Special Guest Professor Miles Prince
Steven Yatomi Clarke on Stocks Down Under
ARTICLES
Follow us and stay connected
